COCM
KDNY

Charter Oak Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Charter Oak Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-600
Closed -$8K – 954
2021
Q3 		$8K Hold
600
– – ﹤0.01% 615
2021
Q2 		$8K Hold
600
– – ﹤0.01% 614
2021
Q1 		$9K Hold
600
– – ﹤0.01% 565
2020
Q4 		$10K Buy
+600
New +$9.05K ﹤0.01% 522

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charter Oak Capital Management's KDNY Position: Q4 2021 in Review

Charter Oak Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2021, closing a stake of 600 shares — an estimated $8K sold.

Charter Oak Capital Management first reported a position in KDNY in Q4 2020 and held it in 4 quarters. The position peaked at $10K in Q4 2020. 103 funds tracked by Wall St. Rank hold KDNY as of Q4 2021.

  • Charter Oak Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Charter Oak Capital Management sold 600 Chinook Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $8K.
  • Charter Oak Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Charter Oak Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $10K in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Charter Oak Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.